Align Technology, Inc. ALGN
- Market cap
- $10.4B
- P/E
- 25.5×
Follow ALGN
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 57.31 | 88.56 | 188.57 | 169.84 | 127.88 | 494.45 | 172.05 | 176.34 | 196.09 | 122.00 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 102.10 | 266.41 | 398.88 | 334.64 | 543.65 | 737.45 | 658.50 | 413.20 | 335.40 | 237.23 |
High Price
|
|||
| 6,060 | 8,715 | 11,660 | 14,530 | 18,070 | 22,540 | 23,165 | 21,610 | 20,945 | 20,290 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 1,080 | 1,473 | 1,966 | 2,407 | 2,472 | 3,953 | 3,735 | 3,862 | 3,999 | 4,035 |
Revenue
|
|||
| 75.50% | 75.81% | 73.63% | 72.46% | 71.33% | 74.26% | 70.52% | 70.08% | 70.00% | 67.19% |
Gross Margin
|
|||
| 243 | 365 | 467 | 563 | 379 | 1,012 | 599 | 641 | 609 | 585 |
EBT
|
|||
| 22.46% | 24.76% | 23.73% | 23.38% | 15.33% | 25.61% | 16.04% | 16.60% | 15.23% | 14.51% |
EBT Margin
|
|||
| 190 | 231 | 400 | 443 | 1,776 | 772 | 362 | 445 | 421 | 410 |
Net Income
|
|||
| 24 | 38 | 55 | 79 | 94 | 109 | 126 | 142 | 145 | 237 |
Depreciation
|
|||
| 13.52 | 18.40 | 24.56 | 30.30 | 31.39 | 50.09 | 47.76 | 50.54 | 53.41 | 55.62 |
Revenue/Sh
|
|||
| 2.38 | 2.89 | 5.00 | 5.57 | 22.55 | 9.78 | 4.62 | 5.82 | 5.63 | 5.66 |
Earnings/Sh
|
|||
| 3.10 | 5.48 | 6.93 | 9.41 | 8.41 | 14.86 | 7.27 | 10.28 | 9.86 | 8.18 |
Cash Flow/Sh
|
|||
| (0.88) | (2.44) | (2.79) | (1.88) | (1.97) | (5.08) | (3.73) | (2.33) | (1.54) | (1.41) |
Capex/Sh
|
|||
| 2.22 | 3.03 | 4.14 | 7.52 | 6.44 | 9.78 | 3.54 | 7.96 | 8.32 | 6.77 |
Free CF/Sh
|
|||
| 12.46 | 14.41 | 15.65 | 16.95 | 41.06 | 45.91 | 46.06 | 47.50 | 51.44 | 55.82 |
Book Value/Sh
|
|||
| 80 | 80 | 80 | 79 | 79 | 79 | 78 | 76 | 75 | 73 |
Shares
|
|||
| 40.74 | 77.72 | 41.89 | 50.10 | 23.66 | 67.20 | 45.95 | 46.13 | 37.10 | 27.59 |
PE Ratio
|
|||
| 7.17 | 12.21 | 8.53 | 9.21 | 17.03 | 13.12 | 4.44 | 5.32 | 3.90 | 2.81 |
PS Ratio
|
|||
| 7.78 | 15.58 | 13.38 | 16.46 | 13.01 | 14.32 | 4.61 | 5.66 | 4.05 | 2.80 |
PB Ratio
|
|||
| 6.58 | 11.72 | 8.15 | 8.85 | 16.64 | 12.82 | 4.18 | 5.07 | 3.64 | 2.54 |
EV/Sales
|
|||
| 40.11 | 71.10 | 48.38 | 35.63 | 81.08 | 65.71 | 56.35 | 32.20 | 23.40 | 20.85 |
EV/FCF
|
|||
| 248 | 439 | 555 | 747 | 662 | 1,173 | 569 | 786 | 738 | 593 |
Op' Cash Flow
|
|||
| (71) | (196) | (223) | (150) | (155) | (401) | (292) | (178) | (116) | (102) |
Capex
|
|||
| 177 | 243 | 331 | 598 | 507 | 771 | 277 | 608 | 623 | 491 |
FCF
|
|||
| 599 | 658 | 610 | 662 | 524 | 570 | 499 | 380 | 454 | 697 |
Working Cap'
|
|||
| — | — | — | 59 | 86 | 126 | 127 | — | — | — |
Total Debt
|
|||
| (640) | (722) | (735) | (869) | (961) | (1,171) | (1,000) | (973) | (1,044) | (1,095) |
Net Debt
|
|||
| 995 | 1,154 | 1,253 | 1,346 | 3,234 | 3,623 | 3,601 | 3,630 | 3,852 | 4,049 |
Sh' Equity
|
|||
| 14.85% | 14.55% | 20.86% | 19.45% | 48.45% | 14.33% | 6.08% | 7.40% | 6.85% | 6.59% |
ROA
|
|||
| 43.81% | 51.07% | 56.34% | 71.00% | 10.65% | 24.89% | 15.44% | 15.13% | 13.52% | 11.55% |
ROIC
|
|||
| 20.58% | 21.53% | 33.25% | 34.07% | 77.55% | 22.52% | 10.01% | 12.31% | 11.26% | 10.39% |
ROE
|
|||
Align Technology, Inc. peers in Medical Instruments & Supplies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| AVTR Avantor, Inc. | $10.4B | 0.0× | Compare |
| COO The Cooper Companies, Inc. | $10.5B | 18.9× | Compare |
| RGEN Repligen Corporation | $10.8B | 253× | Compare |
| BAX Baxter International Inc. | $12.2B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ATR AptarGroup, Inc. | $7.8B | 22.1× | Compare |
| SOLV Solventum Corporation | $15.1B | 10.9× | Compare |
| BLCO Bausch + Lomb Corporation | $6.0B | 0.0× | Compare |
| STVN Stevanato Group S.p.A. | $5.8B | 37.7× | Compare |
ALGN metrics, ten years each
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
Align Technology, Inc. (ALGN) key facts
- Align Technology, Inc. (ALGN) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
- Align Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, up 0.90% from fiscal 2024.
- Net income was $410.4 million, or $5.66 per share (basic), a net margin of 10.2%.
- As of September 25, 2026, ALGN traded at $146.78, a market capitalization of $10.4 billion.
- At that price the stock trades at 25.5× trailing-twelve-month earnings and 2.5× sales.
- Return on equity was 10.4% and debt-to-equity 0.00.
Align Technology, Inc. (ALGN) Latest News
18 Sep
Align Technology identifies sustained Invisalign growth runway despite consumer headwinds. Positive Invisalign growth outlook may support ALGN trajectory amid consumer pressures.
5 Sep
Align Technology (ALGN) could be 24% undervalued based on mixed earnings guidance. Mixed earnings guidance affects Align Technology valuation and near-term market performance without major trajectory shift.
28 Aug
Align Technology stock fell 8.4% since its most recent earnings report amid weaker guidance and softer demand trends. Post-earnings share decline points to near-term pressure on financial results and sentiment but does not indicate structural change.
17 Aug
U.K. VAT ruling threatens to reshape Align Technology's 2026 earnings outlook through higher costs or pricing adjustments. U.K. VAT ruling carries potential to materially alter Align Technology's 2026 earnings trajectory and investor sentiment.
7 Aug
Align Technology (ALGN) released its Q2 2026 earnings call transcript covering financial results, operational metrics and executive outlook. Quarterly earnings updates typically deliver moderate influence on near-term sentiment and valuation without guaranteeing structural shifts.
4 Aug
Align Technology reported Q2 clear aligner volume growth but issued guidance flagging a scanner mix shift. Q2 aligner volume growth offset by scanner mix shift guidance creates moderate near-term operational and sentiment effects.
30 Jul
ALGN Q2 earnings call emphasized digital growth push to drive innovation and expand market presence. Digital growth push signals major strategic moves likely to alter trajectory and investor sentiment.
Align Technology, Inc. released its Q2 2026 earnings call summary covering quarterly financial results, revenue figures, operational updates, and forward-looking guidance. Quarterly earnings data and guidance directly influence stock valuation and investor positioning for the company.
Align Technology Inc posted record revenue in Q2 2026 earnings call with emphasis on clear aligner growth. Record revenue points to strong demand that can lift future financial results and investor outlook.
Align Technology reported record Q2 revenue. Questions remain on whether the stock trades below fair value. Record revenue signals solid financial results that may lift near-term sentiment without shifting long-term strategy.
ALGN stock rose after Q2 earnings and revenue exceeded forecasts, with margins expanding. Q2 earnings beat and margin gains signal stronger financial results with moderate effects on near-term performance and sentiment.
29 Jul
Align Technology Q2 earnings call highlights financial results, operational updates and forward guidance for the company. Q2 earnings results and guidance typically drive major shifts in investor views and stock trajectory.
Align Technology, Inc. (ALGN) will overhaul its board following engagement with Elliott. Board overhaul after activist engagement signals major governance changes that can shift strategy and investor sentiment.
Align Technology announces strategic initiatives aligned with long-term growth and shareholder value creation objectives. Strategic initiatives target sustained growth and value creation that can materially shift company trajectory.
Align Technology announces second quarter 2026 financial results. Q2 2026 financial results release supplies core performance metrics that drive investor sentiment and valuation shifts.
Align Technology hosts 2026 Invisalign Ortho Summit to showcase vision for connected digital orthodontics. Event highlights product innovation in digital orthodontics with moderate potential to influence positioning.
Align Technology reported Q2 earnings with key metrics showing quarterly financial performance, revenue trends, and operational details for the period. Q2 earnings data typically influences near-term investor views on results without fundamentally shifting long-term strategy or positioning.
Align Technology beat Q2 earnings and revenue estimates. Q2 earnings beat signals stronger quarterly financial performance than expected.
23 Jul
Align Technology announces new innovations advancing Invisalign treatment planning and patient engagement via its Align Digital Platform. Core Invisalign innovations strengthen competitive positioning and growth trajectory.
Align Technology maintains competitive position in clear aligners amid market challenges, supporting investor retention of ALGN stock for now. Stock retention advice signals moderate influence on sentiment without major trajectory shifts.
30 Jun
EU launches antitrust probe into Align Technology for allegedly tying Invisalign aligners to its scanners. Antitrust probe over product tying risks fines, remedies, and revenue loss in Europe.
Align Technology issued a statement regarding proceedings initiated by the European Commission. Regulatory proceedings by the European Commission may affect Align Technology's EU operations and market position.
3 Jun
Align Technology promotes AI-powered digital dentistry platform as expansion beyond Invisalign. Platform expansion beyond Invisalign marks major strategic push into broader digital dentistry markets.
28 May
Align Technology unveils new Invisalign solutions, rolls out patient financing programs, and advances global market expansion initiatives. New Invisalign products, financing options and global growth moves strengthen product pipeline and revenue outlook.
27 May
Align Technology achieves record aligner shipments. Stifel stays bullish with $210 price target. Record shipments indicate stronger demand while sustained analyst support may lift near-term sentiment.
25 May
Align Technology to build $200m manufacturing facility in India to expand production capacity. New facility expands capacity and supports international growth strategy.
Align Technology to establish $200m manufacturing facility in India. $200m India plant marks major capacity expansion and market growth move.
Align Technology invests US$200 million in a new India manufacturing plant to advance global expansion and operational efficiency. US$200 million India plant marks major capital outlay that can materially expand capacity and Asian market access.
22 May
Align Technology plans a new multi-million dollar manufacturing facility in Hyderabad, India to expand global operations. New facility adds production capacity and supports Asian market growth without fundamentally altering company trajectory.
20 May
Align Technology exhibits strong growth drivers in clear aligners, expanding market share, and solid financials that support adding the stock to portfolios for potential gains. Positive outlook on Align's core operations and market position points to moderately noticeable influence on future performance without major trajectory shifts.